Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.

Background: Accurate disease detection is integral to risk stratification in B-cell acute lymphoblastic leukemia (ALL). The gold standard used to evaluate response in the United States includes morphologic evaluation and minimal residual disease (MRD) testing of aspirated bone marrow (BM) by flow cy...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Blood & Cancer Vol. 67; no. 4; pp. 1 - 9
Autores principales: Shalabi, Haneen, Yuan, Constance M., Kulshreshtha, Amita, Dulau‐Florea, Alina, Salem, Dalia, Gupta, Gaurav K., Roth, Mark, Filie, Armando C., Yates, Bonnie, Delbrook, Cindy, Derdak, Joanne, Mackall, Crystal L., Lee, Daniel W., Fry, Terry J., Wayne, Alan S., Stetler‐Stevenson, Maryalice, Shah, Nirali N., Dulau-Florea, Alina, Stetler-Stevenson, Maryalice
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Apr2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141878898&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 141878898
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15455009
        1XL2
      jtl: Pediatric Blood & Cancer
      issn: 15455009
      maglogo: Y
    pubinfo:
      dt: Apr2020
      vid: 67
      iid: 4
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        141878898
        141878898
        145849977
        NLM31981407
        141878898
        10.1002/pbc.28149
        NLM31981407
        141878898
      ppf: 1
      ppct: 8
      formats:
      tig:
        atl: Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.
      aug:
        au:
          Shalabi, Haneen
          Yuan, Constance M.
          Kulshreshtha, Amita
          Dulau‐Florea, Alina
          Salem, Dalia
          Gupta, Gaurav K.
          Roth, Mark
          Filie, Armando C.
          Yates, Bonnie
          Delbrook, Cindy
          Derdak, Joanne
          Mackall, Crystal L.
          Lee, Daniel W.
          Fry, Terry J.
          Wayne, Alan S.
          Stetler‐Stevenson, Maryalice
          Shah, Nirali N.
          Dulau-Florea, Alina
          Stetler-Stevenson, Maryalice
        affil: Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda Maryland
      sug:
        subj:
          Neoplastic Processes Pathology
          Hematopoietic Stem Cell Transplantation Methods
          Flow Cytometry Methods
          Bone Marrow Pathology
          Leukemia, Lymphocytic, Acute Pathology
          Neoplasm Recurrence, Local Pathology
          Female
          Adolescence
          Neoplastic Processes Therapy
          Neoplasm Recurrence, Local Therapy
          Immunophenotyping
          Leukemia, Lymphocytic, Acute Therapy
          Male
          Prospective Studies
          Child, Preschool
          Retrospective Design
          Adult
          Young Adult
          Child
          Prognosis
          Impact of Events Scale
          Scales
          Funding Source
          Adolescent: 13-18 years
          Child, Preschool: 2-5 years
          Adult: 19-44 years
          Child: 6-12 years
          Female
          Male
      ab: Background: Accurate disease detection is integral to risk stratification in B-cell acute lymphoblastic leukemia (ALL). The gold standard used to evaluate response in the United States includes morphologic evaluation and minimal residual disease (MRD) testing of aspirated bone marrow (BM) by flow cytometry (FC). This MRD assessment is usually made on a single aspirate sample that is subject to variability in collection techniques and sampling error. Additionally, central nervous system (CNS) assessments for ALL include evaluations of cytopathology and cell counts, which can miss subclinical involvement.Procedure: We retrospectively compared BM biopsy, aspirate, and FC samples obtained from children and young adults with relapsed/refractory ALL to identify the frequency and degree of disease discrepancies in this population. We also compared CNS FC and cytopathology techniques.Results: Sixty of 410 (14.6%) BM samples had discrepant results, 41 (10%) of which were clinically relevant as they resulted in a change in the assignment of marrow status. Discrepant BM results were found in 28 of 89 (31.5%) patients evaluated. Additionally, cerebrospinal fluid (CSF) FC identified disease in 9.7% of cases where cytopathology was negative.Conclusions: These results support further investigation of the role of concurrent BM biopsy, with aspirate and FC evaluations, and the addition of FC to CSF evaluations, to fully assess disease status and response, particularly in patients with relapsed/refractory ALL. Prospective studies incorporating more comprehensive analysis to evaluate the impact on clinical outcomes are warranted.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N